Disease | hyperthermia |
Comorbidity | |neutropenia |
Sentences | 77 |
PubMedID- 21559248 | Dose-limiting toxicity was defined as grade 3 fatigue persisting for ≥7 days or grade 4 fatigue; grade 3 or 4 nausea, diarrhea, or vomiting despite maximum supportive care; symptomatic pulmonary embolism (incidental asymptomatic pulmonary embolism or deep vein thrombosis identified during routine tumor imaging procedures was not dlts); grade 3 or 4 neutropenia with fever >38.5°c; grade 4 neutropenia (absolute neutrophil count <0.5 × 109/l) or thrombocytopenia (platelet count <25 × 109/l) for >7 days; grade 4 hypertension; grade 4 rash/desquamation; grade 4 hypertension; ast or alt >10 × uln; symptomatic hypomagnesemia despite intravenous magnesium replacement; any other motesanib- and/or panitumumab-related grade 4 hematologic or grade 3 nonhematologic toxicity that was unacceptable in duration during the dlt period (cycle 1). |
PubMedID- 23339978 | The predominant toxicity was grade 3-4 neutropenia, occurring in 92% of the patients, although febrile neutropenia arose in 10% of the patients. |
PubMedID- 23056805 | For the last fifty years, fever has been recognized as a major sign of infection in neutropenic patients; one of the great successes in oncology, i.e., reduction in the mortality of cancer patients, has been achieved through the routine use of empiric antibiotics in febrile patients with neutropenia since 1970 [2, 3]. |
PubMedID- 21883896 | Serum cea levels were even increased under everolimus 5 mg a day as compared to baseline and mildly decreased after increasing the dose to 10 mg. then, because of insurgence of grade 2 anaemia and grade 3 neutropenia with fever and need of antibiotic therapy, everolimus was discontinued until recovery to grade 1 haematological toxicity. |
PubMedID- 26524019 | Methods: blood samples obtained from 76 fever patients with al during neutropenia episodes were detected to analyse single nucleotide polymorphism (snp) in the mbl exoni 54 and nfkappab1-94ins/del attg gene, and analyse the correlation between above-menthioned 2 polymorphisms and fever during neutropenia of al patients after chemotherapy. |
PubMedID- 23293699 | Grade 3 fatigue, dehydration, diarrhea, neutropenia with or without fever, lymphopenia, anemia, hyperbilirubinemia, and transaminitis occurred in >/=10% of the patients. |
PubMedID- 20723212 | Chemotherapy-induced neutropenia (cin) can lead to febrile neutropenia (fn), which is associated with considerable morbidity, mortality and costs [4]. |
PubMedID- 23232172 | The most relevant grade 3 or higher adverse events were pneumonia, neutropenia (7% of patients developed febrile neutropenia), thrombocytopenia, anemia, and transaminase elevation [26]. |
PubMedID- 23869563 | Background: a new national guideline for the management of febrile patients with severe neutropenia uses a risk stratification score to tailor treatment. |
PubMedID- 23080291 | Of the 71 patients who developed neutropenia, the proportion of children who developed fever was significantly lower in the ciprofloxacin group than in the placebo group (17/34 [50.0%] versus 27/37 [73.0%]; absolute difference in risk, -23.0%; 95% confidence interval: -45.0% to -0.9%; p = 0.046). |
PubMedID- 22805331 | Dose-limiting toxicities were defined as adverse events (aes) attributed as being possibly, probably, or definitely related to the study agents, and fulfilling one of the following criteria: (a) grade 3 or 4 neutropenia complicated by fever ⩾38.5 °c or infection, or grade 4 neutropenia of at least 7 days duration, (b) grade 3 thrombocytopenia complicated by haemorrhage or grade 4 thrombocytopenia, or (c) any grade 3 or higher non-haematologic toxicity (except fatigue, anorexia, nausea, vomiting, or diarrhoea that was not optimally controlled with appropriate medical intervention). |
PubMedID- 22634531 | The most frequent grade 3 or 4 toxicities were neutropenia (with one febrile neutropenia) and asthenia. |
PubMedID- 21563549 | Except for neutropenia with neutropenic fever and alopecia, no nci-ctc grade iii or iv toxicity was observed. |
PubMedID- 23088794 | The overall favorable response rate (rr) was 64.8% when the resolution of fever during neutropenia was included in the response criteria and 84.5% when excluded. |
PubMedID- 24722996 | Consistent with these findings, neutrophils exposed to non-glycosylated g-csf may be less effective in preventing febrile episodes in patients with chemotherapy-related neutropenia when compared with those exposed to glycosylated g-csf [16, 17]. |
PubMedID- 20509945 | Only patients that presented fever during neutropenia (defined as a neutrophil count <500 μl) were included in the second phase of the study. |
PubMedID- 24793316 | Dengue fever as a cause of febrile neutropenia in adult acute lymphoblastic leukemia: a single center experience. |
PubMedID- 24064965 | Molecular-based diagnosis of bacteremia in the setting of fever with or without neutropenia in pediatric hematology-oncology patients. |
PubMedID- 21906359 | Antibiotic therapy must be initiated immediately in febrile patients with neutropenia, especially when criteria of severe sepsis are met [1,2]. |
PubMedID- 21035352 | The main adverse effect was neutropenia, 15% of the patients experiencing febrile neutropenia. |
PubMedID- 22606398 | Filgrastim as a rescue therapy for persistent neutropenia in a case of dengue hemorrhagic fever with acute respiratory distress syndrome and myocarditis. |
PubMedID- 23836852 | Severe transient neutropenia with fever and abdominal pain in a 30-year-old man. |
PubMedID- 24250583 | It is used for the treatment of urinary tract infection, chronic prostatitis (3) prophylactically in preventing febrile episodes in patients with neutropenia and cancer (4) in nosocomial pneumonia, meningitis and skin infections (5). |
PubMedID- 21791058 | A dlt was defined as treatment-related grade 3 fatigue for ≥ 7 days or grade 4 fatigue; grade 3 or 4 nausea/vomiting despite maximum supportive care; grade 3 neutropenia with fever > 38.5°c or grade 4 neutropenia; grade 4 thrombocytopenia for ≥ 7 days; grade 4 anemia; grade 4 hypertension; alanine aminotransferase or aspartate aminotransferase > 10 times the upper limit of normal; grade 3 rash for ≥ 7 days despite maximum supportive care or grade 4 rash; grade 3 diarrhea for ≥ 7 days despite maximum supportive care or grade 4 diarrhea; or any other treatment-related hematologic or nonhematologic grade 3 or 4 toxicity (except alopecia) occurring in the first 5 weeks of treatment. |
PubMedID- 24337768 | Dlts were defined as follows: (a) grade 3 or higher neutropenia complicated by fever ≥ 38.5 °c or infection, or grade 4 neutropenia with a duration of 7 days or longer; (b) grade 4 thrombocytopenia, or grade 3 thrombocytopenia requiring transfusion; (c) grade 4 anemia; (d) grade 3 or higher pleural or pericardial effusion, peripheral edema or ascites unresponsive to treatment; (e) uncontrollable grade 3 or higher severe fatigue, anorexia, nausea, vomiting or diarrhea, despite maximal supportive therapy; (f) any other grade 3 or higher toxicities than those described in definitions (d) and (e), except for fever without neutropenia and transient electrolyte abnormality. |
PubMedID- 23989947 | Dose-limiting toxicities (dlts) were evaluated during cycle 1 and were defined as follows: anc <0.5 × 109 per l for >5 days; grade 3 neutropenia with fever (⩾38.5 °c), sepsis or other severe infection; platelet count <25.0 × 109 per l; any other grade 3/4 nonhaematological adverse event (ae) suspected to be treatment related (except for nausea/vomiting without an optimal antiemetic regimen, hypersensitivity reactions and nonclinically relevant biochemical abnormalities); and any delays in the administration of a subsequent plitidepsin dose exceeding 2 weeks, or omissions of the infusions scheduled on days 8 and 15 because of treatment-related aes. |
PubMedID- 19735276 | Fifty-six episodes of persistent fever with neutropenia requiring eaft were recorded among 49 patients. |
Page: 1 2